The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Yakult

Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult

Remedy Kombucha

Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Remedy Kombucha, Australia’s leading producer and distributer of kombucha beverages

Macpac Holdings

Advised Super Retail Group on the acquisition of Macpac, the New Zealand-based outdoor adventure retailer

MorphoSys AG

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Grupo Sidecu

Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund

Hirslanden Private Hospital Group

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

Lion’s stake in Warrnambool Cheese and Butter Factory Company

Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

Lion’s Australian Premium Wine Business – Fine Wine Partners

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity

Fragrance Resources Group

Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland

Bionomics Limited

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

Patties Foods Ltd

Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement

Boehringer Ingelheim

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

Airopack Technology Group AG

Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV

Allied Healthcare

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

Refinancing of syndicated bank debt facilities

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

Tate & Lyle plc

Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company

Kerry Pinnacle

Advised Kerry Group plc, a global leader in food ingredients and flavor technologies, on the sale of its Australian subsidiary Kerry Pinnacle, an integrated manufacturer and distributor of bakery ingredients and prepared bakery products, to Pacific Equity Partners

The Warehouse Group Limited

Advised Woolworths Limited, Australia’s largest supermarket operator, on strategic options for the divestment of its 8.8% holding in The Warehouse Group, New Zealand’s largest general merchandise retailer

Lion's Everyday Cheese Business

Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Everyday Cheese business to Warrnambool Cheese & Butter, a listed Australian dairy company controlled by the Canadian dairy player Saputo

Modern Star Pty Ltd

Advised Modern Star, Australia and New Zealand’s #1 supplier of education resources and educational toys, on the sale of 90% of its shares to Navis Capital, a leading private equity group focused on investments in South and Southeast Asia

MannKind Corporation

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Siemens Health Services

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.